Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News

    Latest News - Page 79

    Lupin gets USFDA nod for generic equivalent of UNITHROID to treat thyroid

    Lupin gets USFDA nod for generic equivalent of UNITHROID to treat thyroid

    Medical Dialogues Bureau21 Sept 2019 11:22 AM IST
    Lupin Ltd’s Levothyroxine Sodium Tablets USP, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300...
    AstraZeneca, Ironwood Pharma amend IBS-C drug deal in China

    AstraZeneca, Ironwood Pharma amend IBS-C drug deal in China

    Medical Dialogues Bureau21 Sept 2019 9:30 AM IST
    The amended agreement gives AstraZeneca sole responsibility for developing, manufacturing and commercialising Linzess in China mainland, China Hong...
    Novo Nordisk Tresiba shows lower risk of hypo in adults with Type 2 Diabetes

    Novo Nordisk Tresiba shows lower risk of hypo in adults with Type 2 Diabetes

    Medical Dialogues Bureau21 Sept 2019 9:30 AM IST
    "We are delighted that the findings of the CONCLUDE trial support what we have seen previously across the Tresiba clinical development programme,"...
    Brexit freight plans needed urgently, says drug, medical suppliers

    Brexit freight plans needed urgently, says drug, medical suppliers

    Medical Dialogues Bureau21 Sept 2019 9:00 AM IST
    U.S: Some larger pharmaceutical companies have opted to make their own plans to replenish supplies of critical medicines in the event of a “no-deal”...
    Biocon Chief Kiran Shaw, FM Nirmala Sitharaman in tiff over E-Cigarette ban

    Biocon Chief Kiran Shaw, FM Nirmala Sitharaman in tiff over E-Cigarette ban

    Farhat Nasim20 Sept 2019 5:01 PM IST
    New Delhi: Biocon Chief Kiran Mazumdar Shaw recently got into a spat with the Finance Minister Nirmala Sitharaman on Thursday. The minister defended...
    Upcoming Pharma City project to generate Rs 64000 crore investments: Minister informs Telangana assembly

    Upcoming Pharma City project to generate Rs 64000 crore investments: Minister informs Telangana assembly

    Medical Dialogues Bureau20 Sept 2019 2:33 PM IST
    The Hyderabad Pharma City project has received an overwhelming response from the industry stakeholders, Telangana Minister for IT and Industries KT...
    Novartis combination therapy with Vildagliptin-Metformin shows positive results for Type 2 Diabetes

    Novartis combination therapy with Vildagliptin-Metformin shows positive results for Type 2 Diabetes

    Farhat Nasim20 Sept 2019 9:45 AM IST
    The vildagliptin and metformin dual therapy are used when the patient’s T2DM is insufficiently controlled by metformin monotherapy.Mumbai: Novartis...
    Merck Ebola Vaccine V920 up for USFDA review

    Merck Ebola Vaccine V920 up for USFDA review

    Medical Dialogues Bureau20 Sept 2019 9:30 AM IST
    New Delhi: Merck, known as MSD outside the United States and Canada, recently announced that the U.S. Food and Drug Administration (FDA) has accepted...
    GSK fights bid to strike new Zofran preemption evidence

    GSK fights bid to strike new Zofran preemption evidence

    Medical Dialogues Bureau20 Sept 2019 9:00 AM IST
    U.S. District Judge F. Dennis Saylor during a hearing in Boston asked why some of GSK's witnesses should be allowed to put forward new opinions to...
    Lupin gets USFDA warning letter for Mandideep Unit-1 facility

    Lupin gets USFDA warning letter for Mandideep Unit-1 facility

    Medical Dialogues Bureau19 Sept 2019 1:07 PM IST
    Commenting on the same, Lupin said, "The Company does not believe that the warning letter will have an impact on the disruption of supplies or the...
    Twin Approvals: Abbott bags CE Mark for its Mechanical Heart Valve and Occluder devices

    Twin Approvals: Abbott bags CE Mark for its Mechanical Heart Valve and Occluder devices

    Medical Dialogues Bureau19 Sept 2019 12:17 PM IST
    ABBOTT PARK -- Abbott today announced approvals in Europe for two of its life-saving pediatric devices. The Masters HP™ 15mm rotatable mechanical...
    Mylan launches generic version of Faslodex Injection to treat breast cancer

    Mylan launches generic version of Faslodex Injection to treat breast cancer

    Medical Dialogues Bureau19 Sept 2019 9:35 AM IST
    New Delhi: Mylan N.V. recently announced the U.S. launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, a generic...
    PrevNext

    Popular Stories

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    Supreme Court to hear PIL seeking direction to govt for banning unregulated medical devices

    Supreme Court to hear PIL seeking direction to govt for banning unregulated medical devices

    FDA shuts six medical stores in Haryana due to irregularities

    FDA shuts six medical stores in Haryana due to irregularities

    BA/BE study applications have to be processed in 15 days: CDSCO

    BA/BE study applications have to be processed in 15 days: CDSCO

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

    Coronavirus: CDSCO issues guidelines to be followed while visiting CDSCO office.

    Coronavirus: CDSCO issues guidelines to be followed while visiting CDSCO office.

    AYUSH ministry launches e-AUSHADHI portal for online licensing of drugs

    AYUSH ministry launches e-AUSHADHI portal for online licensing of drugs

    Religare Enterprises to divest stake in arm to Kedaara for Rs 200 crore

    Religare Enterprises to divest stake in arm to Kedaara for Rs 200 crore

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok